CD8 agonism functionally activates memory T cells and enhances antitumor immunity
- Int J Cancer. 2022 Sep 1;151(5):797-808. doi: 10.1002/ijc.34059.
- 1. T Cell Metabolism Group (D192), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- 2. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
- 3. Metabolomics Core Technology Platform, Centre for Organismal Studies (COS), Heidelberg University, Heidelberg, Germany.
- 4. Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany.
Memory CD8+ T cells mature after antigen clearance and ultimately express CD8 protein at levels higher than those detected in effector CD8+ T cells. However, it is not clear whether engagement of CD8 in the absence of antigenic stimulation will result in the functional activation of T cells. Here, we found that CD8 antibody-mediated activation of memory CD8+ T cells triggered T cell receptor (TCR) downstream signaling, enhanced T cell-mediated cytotoxicity and promoted effector cytokine production in a glucose- and glutamine-dependent manner. Furthermore, pretreatment of memory CD8+ T cells with an agonistic anti-CD8 antibody enhanced their tumoricidal activity in vitro and in vivo. From these studies, we conclude that CD8 agonism activates glucose and glutamine metabolism in memory T cells and enhances the efficacy of memory T cell-based Cancer Immunotherapy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Transmembrane GlycoproteinResearch Areas: Inflammation/Immunology